Spero Therapeutics is developing a pipeline of therapies to treat bacterial infections. With the growing global threat of antibiotic resistance, innovative therapeutic approaches are needed to treat serious infections. Spero is delivering differentiated medicines to help patients suffering from serious rare orphan diseases and life threatening infections. This includes SPR720, an oral antibiotic designed to treat nontuberculous mycobacterial (NTM) pulmonary disease which is the first approved novel agent for NTM.

Spero Therapeutics

Founded: 2013
Location: Cambridge, MA
Employee range: 50 - 200
Clinical stage: Clin3
Therapy area: UTI
Drug types: INF
Lead product: Tebipenem HBr
Funding: $5.9M grant Jul 2019; $77M IPO Nov 2017

Drug notes:

About:

Jobs: